A single dose of respiratory syncytial virus vaccine was effective against infections and associated hospitalizations in veterans aged at least 60 years during the 2023-24 season.

Repeat infections with RSV are believed to be common ... from a targeted pathogen in a proprietary parainfluenza virus 5 vector. Clinical data have shown that administration of our intranasal ...

RSV leads to approximately 1.4 million hospitalizations and over 13,000 in-hospital deaths worldwide among infants under six ...

Nirsevimab-resistant respiratory syncytial virus variants remain rare, but continued molecular surveillance is crucial. Read ...

In primary care settings, the burden of RSV on young children and their guardians often varied between the countries of ...

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector ... and respiratory syncytial virus (RSV).

Variations in temperature, precipitation, and humidity can influence the spread of infectious diseases, including by altering ...

Among older adults in Spain, hospitalization rates from respiratory syncytial virus (RSV) infection increases progressively with age and is more likely among people with other health issues and who ...

Respiratory syncytial virus (RSV) infections are the leading cause of viral death in infants, although RSV-related mortality has decreased since the development and approval of prophylactic ...

The respiratory syncytial virus (RSV) vaccine produced strong immune responses in older adults during its first two seasons of use, according to a new study. The phase 3 randomized controlled ...